BEOVU Versus Eylea in the Treatment of Age-related Macular Neovascular Degeneration

Benha University

Status: Unknown

Conditions: Macula Lutea Degeneration

Treatments: Drug: intravitreal injection

Study type: Interventional

Funder types: Other

Identifiers

NCT04882956

Hamaky11

Details and patient eligibility

About

Age-Related macular neovascularization degeneration occur is a vision threatening condition. The investigators compare the efficacy of BEOVU and Eylea intravitreal treatment in the management.

Full description

Baseline ,and postoperative 1 ,6 and 12 months full ophthalmic examination was done. Procedure included randomized intravitreal injection of Brolucizumab (BEOVU®, Genentech, South Francisco, CA) and of aflibercept (Eylea; Regeneron, Tarrytown,NY)

Enrollment: 40 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• • Age-Related macular neovascularization degeneration

Exclusion criteria

• other causes of macular neovascularization degeneration
• other macular diseases

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Single Blind

---

40 participants in 2 patient groups

BEOVU

Active Comparator group

Description:

Intravitreal injection of BEOVU 3 loading injections ( monthly) then every 3 months

Treatment:

Drug: intravitreal injection

Drug: intravitreal injection

Eylea

Active Comparator group

Description:

Intravitreal injection of Eylea 3 loading injections ( monthly) then every 3 months

Treatment:

Drug: intravitreal injection

Drug: intravitreal injection